# Guardant Health, Inc.: overview

GH · Nasdaq · CIK 1576280 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gh.md) · [Financials](/companies/gh/financials.md) · [Filings](/companies/gh/filings.md) · [Insiders](/companies/gh/insiders.md)

Latest reported revenue: [$335.0m](/filings/0001576280-26-000037.md) for Q2 FY2026, three months to 2026-06-30, from the 10-Q filed Jul 30, 2026 (XBRL us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax, accession 0001576280-26-000037).

## Last eight quarters

| Line item | Unit | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [191](/filings/0001576280-25-000277.md) | [202 d](/filings/0001576280-26-000013.md) | [203](/filings/0001576280-26-000026.md) | [232](/filings/0001576280-26-000037.md) | [265](/filings/0001576280-25-000277.md) | [281 d](/filings/0001576280-26-000013.md) | [302](/filings/0001576280-26-000026.md) | [335](/filings/0001576280-26-000037.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(61.3%)](/filings/0001576280-25-000277.md) | [(62.4%) d](/filings/0001576280-26-000013.md) | [(54.6%)](/filings/0001576280-26-000026.md) | [(45.9%)](/filings/0001576280-26-000037.md) | [(37.3%)](/filings/0001576280-25-000277.md) | [(43.0%) d](/filings/0001576280-26-000013.md) | [(40.2%)](/filings/0001576280-26-000026.md) | [(38.5%)](/filings/0001576280-26-000037.md) |
| Net margin | % | [(56.3%)](/filings/0001576280-25-000277.md) | [(55.0%) d](/filings/0001576280-26-000013.md) | [(46.8%)](/filings/0001576280-26-000026.md) | [(43.0%)](/filings/0001576280-26-000037.md) | [(35.0%)](/filings/0001576280-25-000277.md) | [(45.7%) d](/filings/0001576280-26-000013.md) | [(37.2%)](/filings/0001576280-26-000026.md) | [(35.9%)](/filings/0001576280-26-000037.md) |
| Diluted EPS | $ per share | [(0.88)](/filings/0001576280-25-000277.md) | not reported | [(0.77)](/filings/0001576280-26-000026.md) | [(0.80)](/filings/0001576280-26-000037.md) | [(0.74)](/filings/0001576280-25-000277.md) | not reported | [(0.85)](/filings/0001576280-26-000026.md) | [(0.90)](/filings/0001576280-26-000037.md) |
| Free cash flow | $m | [(55.3) d](/filings/0001576280-25-000277.md) | [(83.4) d](/filings/0001576280-26-000013.md) | [(67.1)](/filings/0001576280-26-000026.md) | [(65.9) d](/filings/0001576280-26-000037.md) | [(45.8) d](/filings/0001576280-25-000277.md) | [(54.2) d](/filings/0001576280-26-000013.md) | [(71.2)](/filings/0001576280-26-000026.md) | [(69.5) d](/filings/0001576280-26-000037.md) |

- Revenue. XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax. Derived values: 12-month figure less the 9-month figure.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment. Derived values: 9-month figure less the 6-month figure; 12-month figure less the 9-month figure; 6-month figure less the 3-month figure.

## Last five fiscal years

| Line item | Unit | FY2021 (2021-12-31) | FY2022 (2022-12-31) | FY2023 (2023-12-31) | FY2024 (2024-12-31) | FY2025 (2025-12-31) |
| --- | --- | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [374](/filings/0001576280-24-000043.md) | [450](/filings/0001576280-25-000044.md) | [564](/filings/0001576280-26-000013.md) | [739](/filings/0001576280-26-000013.md) | [982](/filings/0001576280-26-000013.md) |
| Gross margin | % | not reported | not reported | not reported | not reported | not reported |
| Operating margin | % | [(110.0%)](/filings/0001576280-24-000043.md) | [(121.1%)](/filings/0001576280-25-000044.md) | [(100.1%)](/filings/0001576280-26-000013.md) | [(60.0%)](/filings/0001576280-26-000013.md) | [(44.5%)](/filings/0001576280-26-000013.md) |
| Net margin | % | [(103.0%)](/filings/0001576280-24-000043.md) | [(145.6%)](/filings/0001576280-25-000044.md) | [(85.0%)](/filings/0001576280-26-000013.md) | [(59.0%)](/filings/0001576280-26-000013.md) | [(42.4%)](/filings/0001576280-26-000013.md) |
| Diluted EPS | $ per share | [(4.00)](/filings/0001576280-24-000043.md) | [(6.41)](/filings/0001576280-25-000044.md) | [(4.28)](/filings/0001576280-26-000013.md) | [(3.56)](/filings/0001576280-26-000013.md) | [(3.32)](/filings/0001576280-26-000013.md) |
| Free cash flow | $m | [(284)](/filings/0001576280-24-000043.md) | [(387)](/filings/0001576280-25-000044.md) | [(345)](/filings/0001576280-26-000013.md) | [(275)](/filings/0001576280-26-000013.md) | [(233)](/filings/0001576280-26-000013.md) |

- Revenue. XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Gross margin (gross profit / revenue). XBRL Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Operating margin (operating income / revenue). XBRL Operating income: us-gaap:OperatingIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Net margin (net income / revenue). XBRL Net income: us-gaap:NetIncomeLoss; Revenue: us-gaap:Revenues; Revenue: us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
- Diluted EPS. XBRL Diluted EPS: us-gaap:EarningsPerShareDiluted.
- Free cash flow (operating cash flow − capital expenditure). XBRL Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities; Capital expenditure: us-gaap:PaymentsToAcquirePropertyPlantAndEquipment.

Each value links to the filing it came from. d marks a derived value. A ratio is not reported when any input is missing.

## Insider purchases and sales

The last 20 open-market transactions on Form 4 (codes P and S). Reported price is as stated on the form, not a market price. [All insider transactions](/companies/gh/insiders.md)

None in coverage.

## Funds that report holding it

From each manager’s latest Form 13F, largest reported value first. Reported value is as filed: filing data, not a price. [All funds](/funds.md)

| Fund | Quarter ended | Reported value | Shares | Put or call | Change on the quarter before |
| --- | --- | ---: | ---: | --- | --- |
| [BlackRock, Inc.](/funds/2012383.md) | 2026-06-30 | $1.14bn | 7,622,935 |  | Reduced −3,930,824 |
| [VANGUARD CAPITAL MANAGEMENT LLC](/funds/2100119.md) | 2026-06-30 | $863.6m | 5,755,857 |  | Added +131,677 |
| [FMR LLC](/funds/315066.md) | 2026-06-30 | $823.4m | 5,488,272 |  | Added +1,372,191 |
| [VANGUARD PORTFOLIO MANAGEMENT LLC](/funds/2100121.md) | 2026-06-30 | $817.0m | 5,445,785 |  | Reduced −392,207 |
| [Invesco Ltd.](/funds/914208.md) | 2026-06-30 | $664.6m | 4,429,755 |  | Reduced −516,714 |
| [GOLDMAN SACHS GROUP INC](/funds/886982.md) | 2026-06-30 | $566.5m | 3,775,895 |  | Reduced −659,944 |
| [TWO SIGMA INVESTMENTS, LP](/funds/1179392.md) | 2026-06-30 | $558.0m | 3,719,301 |  | Reduced −510,230 |
| [Capital International Investors](/funds/1562230.md) | 2026-06-30 | $510.0m | 3,399,604 |  | Reduced −81,714 |
| [Deep Track Capital, LP](/funds/1856083.md) | 2026-06-30 | $509.1m | 3,393,312 |  | Added +55,071 |
| [FRANKLIN RESOURCES INC](/funds/38777.md) | 2026-06-30 | $485.5m | 3,236,065 |  | Reduced −212,128 |

## Recent filings

[All 1,235 filings](/companies/gh/filings.md)

| Filed | Accepted | Form | What it is | Accession |
| --- | --- | --- | --- | --- |
| 2026-07-30 | 20:46 ET | [10-Q](/filings/0001576280-26-000037.md) | Quarterly report, period 2026-06-30 | 0001576280-26-000037 |
| 2026-07-30 | 20:08 ET | [8-K](/filings/0001576280-26-000036.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001576280-26-000036 |
| 2026-06-18 | 20:11 ET | [8-K](/filings/0001193125-26-275864.md) | 5.07 Shareholder vote results | 0001193125-26-275864 |
| 2026-05-07 | 21:16 ET | [10-Q](/filings/0001576280-26-000026.md) | Quarterly report, period 2026-03-31 | 0001576280-26-000026 |
| 2026-05-07 | 20:10 ET | [8-K](/filings/0001576280-26-000024.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001576280-26-000024 |
| 2026-04-28 | 20:46 ET | [DEF 14A](/filings/0001193125-26-187403.md) | Proxy statement, period 2026-06-17 | 0001193125-26-187403 |
| 2026-04-27 | 21:11 ET | [8-K](/filings/0001193125-26-182391.md) | 5.02 Departure or appointment of officers or directors | 0001193125-26-182391 |
| 2026-02-19 | 22:14 ET | [10-K](/filings/0001576280-26-000013.md) | Annual report, period 2025-12-31 | 0001576280-26-000013 |
| 2026-02-19 | 21:12 ET | [8-K](/filings/0001576280-26-000012.md) | 2.02 Results of operations; 9.01 Financial statements and exhibits | 0001576280-26-000012 |
| 2026-01-12 | 11:04 ET | [8-K](/filings/0001576280-26-000004.md) | 2.02 Results of operations; 7.01 Regulation FD disclosure; 9.01 Financial statements and exhibits | 0001576280-26-000004 |

## Latest annual report

[Form 10-K for the fiscal year ended Dec 31, 2025](/filings/0001576280-26-000013.md), filed Feb 19, 2026.

## Forecast league

Q3 FY2026, the quarter ended 2026-09-30, is open for forecasts until the first results filing for it is accepted by EDGAR. Results are due by \[object Promise\]. [Forecast this quarter](/leagues/2026q3/targets/bb68322e-c152-40f2-9769-b1b25f1e59b8)

## About the filer

- CIK: 1576280
- Tickers: GH
- Exchange: Nasdaq
- SIC code: 8071 Services-Medical Laboratories
- State of incorporation: DE
- Filer category: Large accelerated filer

Source: SEC EDGAR, XBRL company facts, the filing index and Forms 4. Last ingested by Listed: Oct 24, 2026, 15:43 ET. No prices; not investment advice.